Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma

Clinical Cancer Research

Volumn 19, Issue 14, 2013, Pages 3925-3935

  Estevez Garcia, Purificacion ^a,b   Lopez Calderero, Iker ^a,b   Molina Pinelo, Sonia ^a   Muñoz Galvan, Sandra ^a   Salinas, Ana ^a   Gomez Izquierdo, Lourdes ^b   Lucena Cacace, Antonio ^a   Felipe Abrio, Blanca ^a   Paz Ares, Luis ^a,b   Garcia Carbonero, Rocio ^a,b   Carnero, Amancio ^a,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; IRINOTECAN; KI 67 ANTIGEN; MESSENGER RNA; OXALIPLATIN; SPINOPHILIN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SMALL INTESTINE CARCINOMA; STOMACH CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROGNOSIS;

EID: 84881172512     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0057     Document Type: Article

References (46)

1. Jemal A, Bray F, CenterMM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Parkin DM. International variation. Oncogene 2004;23:6329-40.
3. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patientswith metastatic colorectal cancer. Ann Oncol 2009;20:244-50.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343: 905-14.
6. Sedivy R, Wolf B, Kalipciyan M, Steger GG, Karner-Hanusch J, Mader RM. Genetic analysis of multiple synchronous lesions of the colon adenoma-carcinoma sequence. Br J Cancer 2000;82: 1276-82.
7. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
8. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
9. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
10. Lamb RF, Going JJ, Pickford I, Birnie GD. Allelic imbalance at NME1 in microdissected primary and metastatic human colorectal carcinomas is frequent but not associated with metastasis to lymph nodes or liver. Cancer Res 1996;56:916-20.
11. Gao X, Porter AT, Honn KV. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 1997;407:41-53.
12. Garcia-Patino E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, et al. Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 1998; 104:119-23.
13. Yu J, Zhou H, Jin Y, Bai J, Yu Y, Geng J, et al. Three distinct regions of allelic deletion on chromosome 17 involved in sporadic gastric cancer. Hepatogastroenterology 2008;55:1487-91.
14. Carnero A. Spinophilin: a new tumor suppressor at 17q21. Curr Mol Med 2012;12:528-35.
15. Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, et al. Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol 2011;225: 73-82.
16. Allen PB, Ouimet CC, Greengard P. Spinophilin, a novel protein phosphatase 1 binding protein localized to dendritic spines. Proc Natl Acad Sci U S A 1997;94:9956-61.
17. Satoh A, Nakanishi H, Obaishi H, Wada M, Takahashi K, Satoh K, et al. Neurabin-II/spinophilin. An actin filament-binding protein with one pdz domain localized at cadherin-based cell-cell adhesion sites. J Biol Chem 1998;273:3470-5.
18. Vivo M, Calogero RA, Sansone F, Calabro V, Parisi T, Borrelli L, et al. The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 2001;276: 14161-9.
19. Hsieh-Wilson LC, Allen PB, Watanabe T, Nairn AC, Greengard P. Characterization of the neuronal targeting protein spinophilin and its interactions with protein phosphatase-1. Biochemistry 1999;38: 4365-73.
20. Ouimet CC, Katona I, Allen P, Freund TF, Greengard P. Cellular and subcellular distribution of spinophilin, a PP1 regulatory protein that bundles F-actin in dendritic spines. J Comp Neurol 2004;479: 374-88.
21. Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, Zhuo M, et al. Spinophilin regulates the formation and function of dendritic spines. Proc Natl Acad Sci U S A 2000;97:9287-92.
22. Ferrer I, Blanco-Aparicio C, Peregrina S, Canamero M, Fominaya J, Cecilia Y, et al. Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle 2011;10:2751-62.
23. Ferrer I, Peregrino S, Canamero M, Cecilia Y, Blanco-Aparicio C, Carnero A. Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle 2011;10:1948-55.
24. Ruiz L, Traskine M, Ferrer I, Castro E, Leal JF, Kaufman M, et al. Characterization of the p53 response to oncogene-induced senescence. PLoS One 2008;3:e3230.
25. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. Breast Cancer Res Treat 2001; 66:135-42.
26. Caduff RF, Svoboda-Newman SM, Ferguson AW, Frank TS. Comparison of alterations of chromosome 17 in carcinoma of the ovary and of the breast. Virchows Arch 1999;434:517-22.
27. Maitra A, Tavassoli FA, Albores-Saavedra J, Behrens C, Wistuba II, Bryant D, et al. Molecular abnormalities associated with secretory carcinomas of the breast. Hum Pathol 1999;30:1435-40.
28. Abujiang P, Mori TJ, Takahashi T, Tanaka F, Kasyu I, Hitomi S, et al. Loss of heterozygosity (LOH) at 17q and 14q in human lung cancers. Oncogene 1998;17:3029-33.
29. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
30. Smith SA, Easton DF, Ford D, Peto J, Anderson K, Averill D, et al. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet 1993;52: 767-76.
31. SjoblomT, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
32. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31: 1869-83.
33. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 2012;1271:58-67.
34. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR- 181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010;70:1793-803.
35. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
36. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
37. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 20-deoxy-5-azacytidineinduced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-44.
38. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998;4:1021-9.
39. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11.
40. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
41. Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol 2006;17(Suppl 10):x315-24.
42. Haneda M, Kojima E, Nishikimi A, Hasegawa T, Nakashima I, Isobe K. Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA-damaging stress-induced phospho-serine 15 of p53. FEBS Lett 2004;567:171-4.
43. Wang W, Figg WD. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther 2008;7:1004-5.
44. Scata KA, El-Deiry WS. p53, BRCA1 and breast cancer chemoresistance. Adv Exp Med Biol 2007;608:70-86.
45. Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist Updat 2003;6:323-8.
46. Esteves SL, Domingues SC, da Cruz e Silva OA, Fardilha M, da Cruz e Silva EF. Protein phosphatase 1alpha interacting proteins in the human brain. OMICS 2012;16:3-17.